The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
出版年份 2022 全文链接
标题
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
作者
关键词
-
出版物
Science Signaling
Volume 15, Issue 749, Pages -
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2022-08-31
DOI
10.1126/scisignal.abn2707
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins
- (2021) Ryosuke Shirasaki et al. Cell Reports
- Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
- (2021) Seraina Faes et al. Frontiers in Cell and Developmental Biology
- Targeting Protein Kinases Degradation by PROTACs
- (2021) Fei Yu et al. Frontiers in Chemistry
- EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
- (2021) Mary Luz Uribe et al. Cancers
- IGF2BP3 From Physiology to Cancer: Novel Discoveries, Unsolved Issues, and Future Perspectives
- (2020) Caterina Mancarella et al. Frontiers in Cell and Developmental Biology
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
- (2020) Maria Krchniakova et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer
- (2020) Vito Amodio et al. Cancer Discovery
- Proteolysis targeting chimeras (PROTACs) for epigenetics research
- (2020) Anja Vogelmann et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
- (2020) Michael J. Bond et al. ACS Central Science
- PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers
- (2020) Rui Liu et al. Cell Death & Disease
- Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders
- (2020) Jianping Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics
- (2020) Jiun-I Lai et al. Frontiers in Oncology
- CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle–Dependent Degradation of CDK2
- (2020) Kristin M. Riching et al. SLAS Discovery
- Acquired Resistance to BET-PROTACs(Proteolysis Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 ligase Complexes
- (2019) Lu Zhang et al. MOLECULAR CANCER THERAPEUTICS
- mTOR: Role in cancer, metastasis and drug resistance
- (2019) Avaniyapuram Kannan Murugan SEMINARS IN CANCER BIOLOGY
- A view on drug resistance in cancer
- (2019) Neil Vasan et al. NATURE
- Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
- (2018) Chengwei Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
- (2018) Sandra Misale et al. CLINICAL CANCER RESEARCH
- Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
- (2018) Philipp M. Cromm et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment
- (2017) Georg E. Winter et al. MOLECULAR CELL
- Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
- (2017) Calla M Olson et al. Nature Chemical Biology
- Targeted protein degradation by PROTACs
- (2017) Taavi K. Neklesa et al. PHARMACOLOGY & THERAPEUTICS
- TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux
- (2016) Ronilda D'Cunha et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
- (2016) Aparajitha Vaidyanathan et al. BRITISH JOURNAL OF CANCER
- ABC transporters as mediators of drug resistance and contributors to cancer cell biology
- (2016) Jamie I. Fletcher et al. DRUG RESISTANCE UPDATES
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis
- (2016) Si Sun et al. PLoS One
- Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status
- (2016) F. Coscia et al. Nature Communications
- Evaluation of P-Glycoprotein Inhibitory Potential Using a Rhodamine 123 Accumulation Assay
- (2016) Elodie Jouan et al. Pharmaceutics
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Pharmacogenomic agreement between two cancer cell line data sets
- (2015) Nicolas Stransky et al. NATURE
- Tissue-based map of the human proteome
- (2015) M. Uhlen et al. SCIENCE
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ
- (2014) Jürgen Cox et al. MOLECULAR & CELLULAR PROTEOMICS
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- Screening Compounds with a Novel High-Throughput ABCB1-Mediated Efflux Assay Identifies Drugs with Known Therapeutic Targets at Risk for Multidrug Resistance Interference
- (2013) Megan R. Ansbro et al. PLoS One
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance
- (2012) K. G. Chen et al. CLINICAL CANCER RESEARCH
- Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors
- (2012) Mukul Minocha et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Lapatinib for Advanced or Metastatic Breast Cancer
- (2012) F. L. Opdam et al. ONCOLOGIST
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells
- (2010) Kerry Reed et al. Epigenetics
- Gene amplification as double minutes or homogeneously staining regions in solid tumors: Origin and structure
- (2010) C. T. Storlazzi et al. GENOME RESEARCH
- The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance
- (2010) K Reed et al. PHARMACOGENOMICS JOURNAL
- Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma
- (2009) Naomi Walsh et al. BMC Urology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now